AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 20th, 2021 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Replimune, Inc. (the “Company”) and Sushil Patel (the “Executive”) as of May 3, 2021.
REPLIMUNE GROUP, INC. RESTRICTED STOCK UNIT GRANT AGREEMENTReplimune Group, Inc. • May 20th, 2021 • Biological products, (no disgnostic substances) • Delaware
Pursuant to the terms of the Amended and Restated Employment Agreement dated May 3, 2021 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of restricted stock units to the Participant on the terms and subject to the conditions set forth herein. The Committee has decided to make this grant of restricted stock units as an inducement material for the Participant to enter into employment with the Company and to align the Participant’s interests with those of the Company and its stockholders. The grant of the restricted stock units provided for herein is intended to constitute an “employment inducement grant” as described in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, and is not being issued under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as amended from time to time (the “Plan”). Capitalized terms used herein and
REPLIMUNE GROUP, INC. NONQUALIFIED STOCK OPTION GRANT AGREEMENTReplimune Group, Inc. • May 20th, 2021 • Biological products, (no disgnostic substances) • Delaware
Pursuant to the terms of the Amended and Restated Employment Agreement dated May 3, 2021 between Replimune, Inc. (the “Company”) and the Participant (as it may be amended from time to time, the “Employment Agreement”), the Company agreed to provide for the grant of an option to acquire shares of Company common stock, $0.001 par value per share (“Company Stock”) to the Participant on the terms and subject to the conditions set forth herein. The Committee has decided to make this nonqualified stock option grant as an inducement material for the Participant to enter into employment with the Company and to align the Participant’s interests with those of the Company and its stockholders. The grant of the option provided for herein is intended to constitute an “employment inducement grant” as described in Rule 5635(c)(4), or any successor provision, of the Nasdaq Listing Rules, and is not being issued under the Replimune Group, Inc. 2018 Omnibus Incentive Compensation Plan, as amended from t
